Factor XIs: Are they the Knockout Round in Next Phase Antithrombotic Therapies?-Hemostasis vs. Thrombosis: What is the Role of Factor XI?

Hemostasis vs. Thrombosis: What is the Role of Factor XI?

Video Transcription

Video Summary

The discussion centers on the coagulation cascade, particularly the differentiation between thrombosis and hemostasis. Jean discusses the role of factor XI in the cascade and presents data suggesting inhibiting factor XI could be an anticoagulant strategy with reduced bleeding risk compared to existing anticoagulants. Factor XI deficiency, which leads to no spontaneous bleeding, suggests potential advantages for targeting it therapeutically. Clinical studies indicate that congenital Factor XI deficiency is associated with a lower risk of cardiovascular events, raising hopes for new treatments. Experts express excitement over the potential for new agents while acknowledging the need for clinical trials. They stress the importance of patient education, appropriate dosing, and lifestyle adaptations to manage bleeding risks in patients using existing anticoagulants. Effective anticoagulation strategies aim to minimize bleeding while preventing thrombosis, highlighting ongoing research to achieve this balance.

Keywords

coagulation cascade

Factor XI

anticoagulant strategy

thrombosis

bleeding risk

clinical trials